KRAS and non-small cell lung carcinoma: In a phase 2 clinical trial, KRAS‐mutant NSCLC patients were assigned to defactinib 400 mg orally b.i.d. based on TP53 and CDKN2A mutation status, showing the PFS rate at 12 weeks of 31% after extensive pretreatment with well tolerated side effects.88